Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2017

Open Access 01-12-2017 | Case report

Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report

Authors: B. M. D. B. Basnayake, A. W. M. Wazil, T. Kannangara, N. V. I. Ratnatunga, S. Hewamana, A. M. Ameer

Published in: Journal of Medical Case Reports | Issue 1/2017

Login to get access

Abstract

Background

Castleman disease is a rare lymphoproliferative disorder presenting with localized or disseminated lymphadenopathy and systemic manifestations. It can be categorized in numerous ways, such as unicentric versus multicentric, histopathological variants (hyaline-vascular, plasma cell, and mixed), or subtypes based on causative viral infections (human immunodeficiency virus, human herpesvirus-8, or Kaposi sarcoma herpesvirus). Presentation ranges from asymptomatic to symptoms involving multiple organs. Even though the exact mechanism of pathogenesis is unknown, treatment is directed toward possible etiologies such as interleukin-6, cluster of differentiation 20, and viral agents.

Case presentation

A 36-year-old Sri Lankan woman presented with generalized body swelling and foamy urine of 2 weeks’ duration. Examination revealed pallor; generalized edema; axillary, cervical, and inguinal lymphadenopathy; hypertension; and hepatomegaly. Investigations showed bicytopenia, nephrotic range proteinuria with hypoalbuminemia, hypogammaglobulinemia, and features of hyaline-vascular type Castleman disease in a lymph node biopsy. She was managed with rituximab and had good clinical improvement.

Conclusions

Castleman disease has a broad spectrum of clinical manifestations, disease pathogeneses, and associations and/or complications. Medical professionals need to be familiar with this spectrum because timely diagnosis and aggressive targeted therapy are the cornerstones of managing these patients.
Literature
1.
go back to reference Bonekamp D, Horton KM, Hruban RH, Fishman EK. Castleman disease: the great mimic. Radiographics. 2011;31(6):1793–807.CrossRefPubMed Bonekamp D, Horton KM, Hruban RH, Fishman EK. Castleman disease: the great mimic. Radiographics. 2011;31(6):1793–807.CrossRefPubMed
2.
go back to reference Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129(1):3–17.CrossRefPubMed Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129(1):3–17.CrossRefPubMed
3.
go back to reference Al-Amri AM, Abdul-Rahman IS, Ghallab KQ. Castleman’s disease: a study of a rare lymphoproliferative disorder in a university hospital. Gulf J Oncolog. 2010;7:25–36. Al-Amri AM, Abdul-Rahman IS, Ghallab KQ. Castleman’s disease: a study of a rare lymphoproliferative disorder in a university hospital. Gulf J Oncolog. 2010;7:25–36.
4.
go back to reference Mah NA, Peretsman SJ, Teigland CM, Banks PM. Castleman disease of the hyaline-vascular type confined to the kidney. Am J Clin Pathol. 2007;127(3):465–8.CrossRefPubMed Mah NA, Peretsman SJ, Teigland CM, Banks PM. Castleman disease of the hyaline-vascular type confined to the kidney. Am J Clin Pathol. 2007;127(3):465–8.CrossRefPubMed
5.
go back to reference Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236–46.CrossRefPubMed Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236–46.CrossRefPubMed
6.
go back to reference Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9:822–30.CrossRefPubMed Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9:822–30.CrossRefPubMed
7.
go back to reference Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–83.CrossRefPubMed Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–83.CrossRefPubMed
8.
go back to reference Lui SL, Chan KW, Li FK, Cheng IK, Chan TM. Castleman’s disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron. 1998;78(3):323–7.CrossRefPubMed Lui SL, Chan KW, Li FK, Cheng IK, Chan TM. Castleman’s disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron. 1998;78(3):323–7.CrossRefPubMed
9.
go back to reference El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26(2):599–609.CrossRefPubMed El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26(2):599–609.CrossRefPubMed
10.
go back to reference Curioni S, D’Amico M, Quartagno R, Martino S, Dell’Antonio G, Cusi D. Castleman’s disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16(7):1475–8.CrossRefPubMed Curioni S, D’Amico M, Quartagno R, Martino S, Dell’Antonio G, Cusi D. Castleman’s disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16(7):1475–8.CrossRefPubMed
11.
go back to reference Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014;21(4):266–78.PubMed Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014;21(4):266–78.PubMed
12.
go back to reference Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman’s disease. Cancer. 1999;85(3):706–17.CrossRefPubMed Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman’s disease. Cancer. 1999;85(3):706–17.CrossRefPubMed
13.
go back to reference Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–6.CrossRefPubMed Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–6.CrossRefPubMed
14.
go back to reference Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82(12):766–8.CrossRefPubMed Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82(12):766–8.CrossRefPubMed
15.
go back to reference Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest. 1997;99(9):2082–6.CrossRefPubMedPubMedCentral Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest. 1997;99(9):2082–6.CrossRefPubMedPubMedCentral
Metadata
Title
Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report
Authors
B. M. D. B. Basnayake
A. W. M. Wazil
T. Kannangara
N. V. I. Ratnatunga
S. Hewamana
A. M. Ameer
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2017
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-017-1294-3

Other articles of this Issue 1/2017

Journal of Medical Case Reports 1/2017 Go to the issue